Tracon Pharma jumps on FDA nod for rare cancer treatment study

TRACON Pharmaceuticals

29/08/2022 13:52

** Drug Developer Tracon Pharmaceuticals Inc's shares
 TCON.O  jump 9.5% to $2.2 before the bell
    ** U.S. FDA clears TCON's application to start an
early-to-mid stage clinical trial of its experimental therapy
YH001 for the treatment of patients with sarcoma  urn:newsml:reuters.com:*:nGNX6Jb6jr
    ** Trial to test YH001 in combination with two other drugs
for sarcoma - a rare type of cancer that occurs in bone and
connective tissues 
    ** Up to Friday's close, stock down ~27% YTD 

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))